Search
Search results 56
AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for selpercatinib RET fusion positive NSCLC
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) as a companion diagnostic for RET fusion-positive non-small cell lung cancer (“NSCLC”), for selpercatinib capsules 40 mg
News & Events
AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for LUMAKRAS® (Sotorasib)
Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyD
News & Events
MHLW Approves AmoyDx® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek® (Entrectinib) in Japan
TOKYO and XIAMEN, August 9, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) had been approved by t
News & Events
Filing Notice for a Manufacturing and Marketing Application for AmoyDx® Pan Lung Cancer PCR Panel as a Companion Diagnostic for a Drug Targeting RET fusion-Positive Non-Small Cell Lung Cancer
TOKYO and XIAMEN, April 20, 2022 -- Riken Genesis Co., Ltd., (“Rigen Genesis”), Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that in April 2022, AmoyDx® Pan Lung Cancer PCR Panel (the “
News & Events
Notice Concerning Application for Partial Revision of Manufacturing and Marketing Approval of Companion Diagnostic Reagent for the AmoyDx® Pan Lung Cancer PCR Panel
TOKYO and XIAMEN, February 24, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that an application for partial revision of manufacturing and marketing approval for Am
News & Events
AmoyDx Announces Its PLC Panel Adopted as Companion Diagnostic for Brigatinib in Japan
Xiamen, China, January 29, 2022 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company today announced that the AmoyDx Pan Lung Cancer PCR Panel (the “PLC Panel”) has been adopted by Takeda Ph
News & Events
AmoyDx and PREMIA Announce the Commercial Launch of the AmoyDx® Pan Lung Cancer PCR Panel in Japan
Xiamen and Hong Kong, January 14, 2022 -- Amoy Diagnostics Co., Ltd., (“AmoyDx”) and PREMIA Holdings (HK) Limited (“PREMIA”) today announced the commercial launch of the AmoyDx® Pan Lung Cancer PCR Panel (the “PLC Panel”) in Japan as a reimbursed companio
News & Events
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for TEPMETKO® (tepotinib)
TOKYO and XIAMEN, August 17, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Ministry of Health, Labour and Welfare (MHLW) has approved the
News & Events
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer
TOKYO and XIAMEN, June 30, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx® PLC Panel”), an i
News & Events
Breaking News! ROS1, EGFR included on health insurance list of SK, TW
Breaking News!
South Korea Includes AmoyDx® ROS1 Kit on National Health Insurance List
Taiwan, China Includes AmoyDx® EGFR Kit on Health Insurance List
News & Events
AmoyDx ROS1 Kit Approval in Taiwan, China
Recently AmoyDx ROS1 gene fusion detection kit (fluorescence PCR method) was approved by Taiwan, China Food and Drug Administration(TFDA).
News & Events
AmoyDx® Essential NGS panel approval from Chinese authority
AmoyDx® Essential NGS panel was approved by Chinese National Medical Products Administration (NMPA) on November 20, 2018, for qualitative detection of gene mutations in patients with Non-Small Cell
News & Events
2018 AmoyDx Distributors Annual Meeting successfully held in Shanghai
November 11, 2018 (Shanghai, China) AmoyDx Distributors Annual Meeting 2018 was held in Shanghai on November 8, 2018. 34 delegates from 19 countries gathered together to get the latest market
News & Events
AmoyDx ROS1 Gene Fusions Detection Kit was Approved by South Korea MFDS as Companion Diagnostics for Pfizer's Crizotinib
News & Events
Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit
Amoy Diagnostics Co., Ltd. (AmoyDx, SHE:300685) announced that NMPA（National Medical Products Administration）approved its Multi-Genes Mutations Detection Kit on Aug 24, 2018.
News & Events
Meet AmoyDx at ELCC 2018 in Switzerland for NSCLC Molecular Testing
Amoy Diagnostics will be exhibiting at the ELCC 2018 in Geneva, Switzerland. Welcome to visit us. The exhibition details are below.
News & Events
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017 was held in Xiamen, China on December 4. Distributors from different countries gathered to get the recent update on precision oncology
News & Events
Visit AmoyDx at MEDICA 2017, Germany
As the world’s largest medical trade fair, MEDICA in Düsseldorf remains the top event for decision-makers from all over the world.
News & Events
Amoy Diagnostics exhibits in the18th World Conference on Lung Cancer(WCLC) in Yokohama, Japan
The 18th World Conference on Lung Cancer (WCLC) was held in Yokohama, Japan this week. It is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, organized by
News & Events
Visit AmoyDx at WCLC 2017 of IASLC in Japan
Amoy Diagnostics will be exhibiting at the IASLC WCLC 2017 in Yokohama, Japan. Welcome to visit us.
News & Events
AmoyDx attended News Conference of Xalkori ROS1 approval in Japan
On June 23, Pfizer Oncology and Merck KGaA held a News Conference in Tokyo launching Xalkori (Crizotinib) ROS1 approval for additional indication. Xalkori, as a lung cancer targeted drug developed by Pfizer.
News & Events
AmoyDx to develop CDx for CANbridge Glioblastoma Candidate
CANbridge Life Sciences will partner with Amoy Diagnostics Co., Ltd. (AmoyDx) to develop a companion diagnostic for its lead candidate, the glioblastoma multiforme (GBM) treatment CAN008, the companies said today, through a collaboration whose value was n
News & Events
AmoyDx in European Lung Cancer Conference (ELCC) 2017
The European Lung Cancer Conference (ELCC) is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, all working towards a shared goal: to advance
News & Events
Visit AmoyDx at ELCC 2017 in Switzerland
Amoy Diagnostics will be exhibiting at the ELCC 2017 in Geneva, Switzerland. Welcome to visit us. The exhibition details are below.
News & Events
AmoyDx ROS1 Fusion Test Kit was Approved by Japanese Authority as Companion Diagnostics Kit for Pfizer's Crizotinib
February 3, 2017 – Amoy Diagnostics of Xiamen, China today announced that it has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its ROS1 fusion PCR assay as a
News & Events
AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer
June 14, 2016, Xiamen, China -- Amoy Diagnostics Co, Ltd. (AmoyDx), a leading provider of cancer molecular diagnostic products and services, announced today that its AmoyDx®ROS1 test successfully supported
News & Events
Amoy Diagnostics Achieved CFDA Approval For Its EGFR&ALK&ROS1 Testing Kit
Amoy Diagnostics Co., Ltd. (AmoyDx), a provider of oncology molecular diagnostics products and services, announced today that it has got Chinese FDA (CFDA) approval for its multiple gene mutations detection
News & Events
Amoy Diagnostics and Illumina Enter Strategic Collaboration for Next-Generation Sequencing Cancer Diagnostics in China
XIAMEN, China & SAN DIEGO--(BUSINESS WIRE)--Amoy Diagnostics Co. Ltd. (ADx) and Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration to accelerate the adoption of precision medicine
News & Events
Pan Lung Cancer PCR Panel
PRODUCTS
Multi-Gene Mutations Detection Kit
PRODUCTS
ROS1 Gene Fusions Detection Kit
PRODUCTS
ALK Gene Fusions and ROS1 Gene Fusions Detection Kit
PRODUCTS
EGFR/ALK/ROS1 Mutations Detection Kit
PRODUCTS
HANDLE Classic NGS Panel
PRODUCTS
Essential NGS Panel
Focus on 10 driver genes for clinical targeted therapy.
PRODUCTS
ROS1-L2-03 Biomarker testing for personalized, firstline therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan
DOWNLOAD
ROS1-L2-01 Testing for ROS1 in non-small cell lung cancer a review with recommendations
DOWNLOAD
EGFR-L2-07 KRAS-L2-03 BRAF-L2-03 PIK3CA-L2-01 ROS1-L2-02 Molecular alterations and clinical prognostic factors for
DOWNLOAD
ROS1-L1-06 AR-L1-01 EAR-L1-01 Prevalence of ROS1 fusion in Chinese patients with non‐small cell lung cancer
DOWNLOAD
ROS1-L1-05 A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib
DOWNLOAD
ROS1-L1-04 Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer
DOWNLOAD
ROS1-L1-03 Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement.
DOWNLOAD
ROS1-L1-02 Detection of lung adenocarcinoma with ROS1 rearrangement by IHC , FISH , and RT-PCR and analysis of its
DOWNLOAD
ROS1-L1-01 ROS1 fusions in Chinese patients with non-small-cell lung cancer
DOWNLOAD
ROS1-2017 WCLC-Clinical validation of a real time PCR assay for the detection of ROS1 fusion in Chinese non-small cell lung cancer
DOWNLOAD
ROS1 Safety Data Sheet
DOWNLOAD
ALKROS1 Safety Data Sheet
DOWNLOAD
EGFRALKROS1 Safety Data Sheet
DOWNLOAD
AmoyDx® EGFR.ALK.ROS1 Mutations Detection Kit-P1.1-8T-RUO
DOWNLOAD
AmoyDx® ROS1 Gene Fusions Detection Kit-B1.0-12T-CE
DOWNLOAD
AmoyDx® ROS1 Gene Fusions Detection Kit-B1.0-12T-RUO
DOWNLOAD
AmoyDx® ALK Gene Fusions and ROS1 Gene Fusions Detection Kit-P1.0-8T-CE
DOWNLOAD
AmoyDx® ALK Gene Fusions and ROS1 Gene Fusions Detection Kit-P1.0-8T-RUO
DOWNLOAD
Result analysis video-ROS1 on ABI7500
Result analysis video-ROS1 on ABI7500
Videos
Result analysis video-ROS1 on LightCycler 480
Result analysis video-ROS1 on LightCycler 480
Videos
Result analysis video-ROS1 on Bio-Rad CFX96
Result analysis video-ROS1 on Bio-Rad CFX96
Videos
no more...
AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for selpercatinib RET fusion positive NSCLC
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) as a companion diagnostic for RET fusion-positive non-small cell lung cancer (“NSCLC”), for selpercatinib capsules 40 mg
News & Events
AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for LUMAKRAS® (Sotorasib)
Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyD
News & Events
MHLW Approves AmoyDx® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek® (Entrectinib) in Japan
TOKYO and XIAMEN, August 9, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) had been approved by t
News & Events
Filing Notice for a Manufacturing and Marketing Application for AmoyDx® Pan Lung Cancer PCR Panel as a Companion Diagnostic for a Drug Targeting RET fusion-Positive Non-Small Cell Lung Cancer
TOKYO and XIAMEN, April 20, 2022 -- Riken Genesis Co., Ltd., (“Rigen Genesis”), Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that in April 2022, AmoyDx® Pan Lung Cancer PCR Panel (the “
News & Events
Notice Concerning Application for Partial Revision of Manufacturing and Marketing Approval of Companion Diagnostic Reagent for the AmoyDx® Pan Lung Cancer PCR Panel
TOKYO and XIAMEN, February 24, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that an application for partial revision of manufacturing and marketing approval for Am
News & Events
AmoyDx Announces Its PLC Panel Adopted as Companion Diagnostic for Brigatinib in Japan
Xiamen, China, January 29, 2022 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company today announced that the AmoyDx Pan Lung Cancer PCR Panel (the “PLC Panel”) has been adopted by Takeda Ph
News & Events
AmoyDx and PREMIA Announce the Commercial Launch of the AmoyDx® Pan Lung Cancer PCR Panel in Japan
Xiamen and Hong Kong, January 14, 2022 -- Amoy Diagnostics Co., Ltd., (“AmoyDx”) and PREMIA Holdings (HK) Limited (“PREMIA”) today announced the commercial launch of the AmoyDx® Pan Lung Cancer PCR Panel (the “PLC Panel”) in Japan as a reimbursed companio
News & Events
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for TEPMETKO® (tepotinib)
TOKYO and XIAMEN, August 17, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Ministry of Health, Labour and Welfare (MHLW) has approved the
News & Events
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer
TOKYO and XIAMEN, June 30, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx® PLC Panel”), an i
News & Events
Breaking News! ROS1, EGFR included on health insurance list of SK, TW
Breaking News!
South Korea Includes AmoyDx® ROS1 Kit on National Health Insurance List
Taiwan, China Includes AmoyDx® EGFR Kit on Health Insurance List
News & Events
AmoyDx ROS1 Kit Approval in Taiwan, China
Recently AmoyDx ROS1 gene fusion detection kit (fluorescence PCR method) was approved by Taiwan, China Food and Drug Administration(TFDA).
News & Events
AmoyDx® Essential NGS panel approval from Chinese authority
AmoyDx® Essential NGS panel was approved by Chinese National Medical Products Administration (NMPA) on November 20, 2018, for qualitative detection of gene mutations in patients with Non-Small Cell
News & Events
2018 AmoyDx Distributors Annual Meeting successfully held in Shanghai
November 11, 2018 (Shanghai, China) AmoyDx Distributors Annual Meeting 2018 was held in Shanghai on November 8, 2018. 34 delegates from 19 countries gathered together to get the latest market
News & Events
AmoyDx ROS1 Gene Fusions Detection Kit was Approved by South Korea MFDS as Companion Diagnostics for Pfizer's Crizotinib
News & Events
Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit
Amoy Diagnostics Co., Ltd. (AmoyDx, SHE:300685) announced that NMPA（National Medical Products Administration）approved its Multi-Genes Mutations Detection Kit on Aug 24, 2018.
News & Events
Meet AmoyDx at ELCC 2018 in Switzerland for NSCLC Molecular Testing
Amoy Diagnostics will be exhibiting at the ELCC 2018 in Geneva, Switzerland. Welcome to visit us. The exhibition details are below.
News & Events
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017 was held in Xiamen, China on December 4. Distributors from different countries gathered to get the recent update on precision oncology
News & Events
Visit AmoyDx at MEDICA 2017, Germany
As the world’s largest medical trade fair, MEDICA in Düsseldorf remains the top event for decision-makers from all over the world.
News & Events
Amoy Diagnostics exhibits in the18th World Conference on Lung Cancer(WCLC) in Yokohama, Japan
The 18th World Conference on Lung Cancer (WCLC) was held in Yokohama, Japan this week. It is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, organized by
News & Events
Visit AmoyDx at WCLC 2017 of IASLC in Japan
Amoy Diagnostics will be exhibiting at the IASLC WCLC 2017 in Yokohama, Japan. Welcome to visit us.
News & Events
AmoyDx attended News Conference of Xalkori ROS1 approval in Japan
On June 23, Pfizer Oncology and Merck KGaA held a News Conference in Tokyo launching Xalkori (Crizotinib) ROS1 approval for additional indication. Xalkori, as a lung cancer targeted drug developed by Pfizer.
News & Events
AmoyDx to develop CDx for CANbridge Glioblastoma Candidate
CANbridge Life Sciences will partner with Amoy Diagnostics Co., Ltd. (AmoyDx) to develop a companion diagnostic for its lead candidate, the glioblastoma multiforme (GBM) treatment CAN008, the companies said today, through a collaboration whose value was n
News & Events
AmoyDx in European Lung Cancer Conference (ELCC) 2017
The European Lung Cancer Conference (ELCC) is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, all working towards a shared goal: to advance
News & Events
Visit AmoyDx at ELCC 2017 in Switzerland
Amoy Diagnostics will be exhibiting at the ELCC 2017 in Geneva, Switzerland. Welcome to visit us. The exhibition details are below.
News & Events
AmoyDx ROS1 Fusion Test Kit was Approved by Japanese Authority as Companion Diagnostics Kit for Pfizer's Crizotinib
February 3, 2017 – Amoy Diagnostics of Xiamen, China today announced that it has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its ROS1 fusion PCR assay as a
News & Events
AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer
June 14, 2016, Xiamen, China -- Amoy Diagnostics Co, Ltd. (AmoyDx), a leading provider of cancer molecular diagnostic products and services, announced today that its AmoyDx®ROS1 test successfully supported
News & Events
Amoy Diagnostics Achieved CFDA Approval For Its EGFR&ALK&ROS1 Testing Kit
Amoy Diagnostics Co., Ltd. (AmoyDx), a provider of oncology molecular diagnostics products and services, announced today that it has got Chinese FDA (CFDA) approval for its multiple gene mutations detection
News & Events
Amoy Diagnostics and Illumina Enter Strategic Collaboration for Next-Generation Sequencing Cancer Diagnostics in China
XIAMEN, China & SAN DIEGO--(BUSINESS WIRE)--Amoy Diagnostics Co. Ltd. (ADx) and Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration to accelerate the adoption of precision medicine
News & Events
no more...
Pan Lung Cancer PCR Panel
PRODUCTS
Multi-Gene Mutations Detection Kit
PRODUCTS
ROS1 Gene Fusions Detection Kit
PRODUCTS
ALK Gene Fusions and ROS1 Gene Fusions Detection Kit
PRODUCTS
EGFR/ALK/ROS1 Mutations Detection Kit
PRODUCTS
HANDLE Classic NGS Panel
PRODUCTS
Essential NGS Panel
Focus on 10 driver genes for clinical targeted therapy.
PRODUCTS
no more...
ROS1-L2-03 Biomarker testing for personalized, firstline therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan
DOWNLOAD
ROS1-L2-01 Testing for ROS1 in non-small cell lung cancer a review with recommendations
DOWNLOAD
EGFR-L2-07 KRAS-L2-03 BRAF-L2-03 PIK3CA-L2-01 ROS1-L2-02 Molecular alterations and clinical prognostic factors for
DOWNLOAD
ROS1-L1-06 AR-L1-01 EAR-L1-01 Prevalence of ROS1 fusion in Chinese patients with non‐small cell lung cancer
DOWNLOAD
ROS1-L1-05 A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib
DOWNLOAD
ROS1-L1-04 Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer
DOWNLOAD
ROS1-L1-03 Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement.
DOWNLOAD
ROS1-L1-02 Detection of lung adenocarcinoma with ROS1 rearrangement by IHC , FISH , and RT-PCR and analysis of its
DOWNLOAD
ROS1-L1-01 ROS1 fusions in Chinese patients with non-small-cell lung cancer
DOWNLOAD
ROS1-2017 WCLC-Clinical validation of a real time PCR assay for the detection of ROS1 fusion in Chinese non-small cell lung cancer
DOWNLOAD
ROS1 Safety Data Sheet
DOWNLOAD
ALKROS1 Safety Data Sheet
DOWNLOAD
EGFRALKROS1 Safety Data Sheet
DOWNLOAD
AmoyDx® EGFR.ALK.ROS1 Mutations Detection Kit-P1.1-8T-RUO
DOWNLOAD
AmoyDx® ROS1 Gene Fusions Detection Kit-B1.0-12T-CE
DOWNLOAD
AmoyDx® ROS1 Gene Fusions Detection Kit-B1.0-12T-RUO
DOWNLOAD
AmoyDx® ALK Gene Fusions and ROS1 Gene Fusions Detection Kit-P1.0-8T-CE
DOWNLOAD
AmoyDx® ALK Gene Fusions and ROS1 Gene Fusions Detection Kit-P1.0-8T-RUO
DOWNLOAD
no more...